Latest Articles about WCRX

Actavis to Buy Warner Chilcott - Analyst Blog

Zacks Equity Research — Wed, 22 May 2013 00:25:25 Z

Actavis, Inc. ( ACT ) recently announced its intention to acquire Warner Chilcott plc ( WCRX ) in a stock-for-stock transaction worth about $8.5 billion. This includes the assumption of

Pre-Market Most Active for May 20, 2013 : WCRX, RDS/B, YHOO, ACT, BAC, BP, AU, NBG, GILD, ASML, WBSN, ZNGA

NASDAQ.com News — Mon, 20 May 2013 16:39:56 Z

The NASDAQ 100 Pre-Market Indicator is to 3,026.98. The total Pre-Market volume is currently 9,282,494 shares traded. The following are the most active stocks for the pre-market session :

Bulls return for dose of Warner Chilcott

David Russell — Thu, 16 May 2013 18:58:33 Z

Irish drug maker Warner Chilcott rallied earlier this month, and the bulls are back today. optionMONSTER's Heat Seeker monitoring program detected the purchase of 6,000 July 19 calls for $1.82

Earnings Beat at Warner Chilcott - Analyst Blog

Zacks Equity Research — Mon, 13 May 2013 18:48:01 Z

Warner Chilcott' s ( WCRX ) first quarter 2013 earnings (excluding special items) of 92 cents per share handsomely beat the Zacks Consensus Estimate of 85 cents. Lower selling, general

Pre-Market Earnings Report for May 10, 2013 : SIRO, WCRX, ERF, DRH, EVEP, BECN, MT, AWR, LXRX, HL, TRLG, STB

NASDAQ.com News — Fri, 10 May 2013 00:00:03 Z

The following companies are expected to report earnings prior to market open on 05/10/2013. Visit our Earnings Calendar for a full list of expected earnings releases. Sirona Dental Systems,

Positive Data on BioLineRx Treatment - Analyst Blog

Zacks Equity Research — Fri, 19 Apr 2013 03:12:18 Z

BioLineRx Ltd. ( BLRX ) recently announced encouraging results from a phase IIa study on BL-7040. BioLineRx is developing BL-7040 for the treatment of inflammatory bowel disease (IBD).

Good News for Warner Chilcott - Analyst Blog

Zacks Equity Research — Tue, 16 Apr 2013 01:50:01 Z

Warner Chilcott plc ( WCRX ) recently received encouraging news from the US Food and Drug Administration (FDA) when the regulatory agency approved the company's acne drug Doryx at 200 mg

Back to Neutral on Warner Chilcott - Analyst Blog

Zacks Equity Research — Thu, 21 Mar 2013 22:32:22 Z

We are reverting to a Neutral recommendation on Warner Chilcott plc ( WCRX ) from Outperform as we believe that the stock is fairly valued at current levels with limited upside potential

Astellas Launches Betmiga in the UK - Analyst Blog

Zacks Equity Research — Tue, 05 Mar 2013 03:50:01 Z

Astellas Pharma, Inc. ( ALPMY ) recently announced the launch of its overactive bladder (OAB) drug, Betmiga (mirabegron), in the UK. Betmiga had gained EU approval for the treatment of OAB

Warner Chilcott Tops in 4Q - Analyst Blog

Zacks Equity Research — Mon, 25 Feb 2013 19:30:01 Z

Warner Chilcott 's ( WCRX ) fourth quarter 2012 earnings (excluding special items) of 91 cents per share handsomely beat the Zacks Consensus Estimate of 73 cents. Lower selling, general

Pre-Market Earnings Report for February 22, 2013 : AGU, FLS, CHTR, EGO, PNW, IPG, NVE, ANF, WCRX, HMSY, POR, B

NASDAQ.com News — Fri, 22 Feb 2013 02:00:04 Z

The following companies are expected to report earnings prior to market open on 02/22/2013. Visit our Earnings Calendar for a full list of expected earnings releases. Agrium Inc. ( AGU )

Warner Chilcott Provides 2013 View - Analyst Blog

Zacks Equity Research — Tue, 12 Feb 2013 04:45:10 Z

Warner Chilcott ( WCRX ) recently revealed its financial guidance for 2013. The company expects to earn $3.20-$3.30 per share on total revenues of $2.3-$2.4 billion in 2013. While revenue

FDA Nod for Warner Chilcott Drug - Analyst Blog

Zacks Equity Research — Sat, 09 Feb 2013 00:00:01 Z

Recently, Warner Chilcott plc ( WCRX ) received encouraging news when the US Food and Drug Administration (FDA) approved its ulcerative colitis drug Delzicol (mesalamine). The company

After Hours Most Active for Feb 6, 2013 : T, BMY, FCX, KMI, NOK, HCBK, QQQ, ELN, GMCR, VMED, NWSA, WCRX

NASDAQ.com News — Thu, 07 Feb 2013 02:44:58 Z

The NASDAQ 100 After Hours Indicator is down -1.61 to 2,744.74. The total After hours volume is currently 36,743,274 shares traded. The following are the most active stocks for the after

Wider Loss at ImmunoGen - Analyst Blog

Zacks Equity Research — Mon, 28 Jan 2013 19:16:01 Z

ImmunoGen Inc. ( IMGN ) reported second quarter fiscal 2013 adjusted loss of 29 cents per share, wider than both the Zacks Consensus Estimate of a loss of 24 cents and the year-ago loss of